VEGFA and hepatocellular carcinoma: The combination of Atezolizumab (anti-programmed death-ligand 1) and Bevacizumab (anti-vascular endothelial growth factor) has emerged as a new standard for patients with advanced HCC (5), offering a therapy that modulates the HCC microenvironment.